ASX:MSBBiotechs
Mesoblast (ASX:MSB) Is Up 9.2% After Ryoncil’s Near-US$100m Debut And Revascor FDA Progress – Has The Bull Case Changed?
Earlier this week, Mesoblast reported that Ryoncil’s first-year US launch revenue approached about US$100 million, alongside continued FDA engagement on an accelerated-approval pathway and Biologics License Application for heart failure therapy Revascor.
This combination of early commercial traction for Ryoncil and active regulatory dialogue on Revascor has sharpened investor focus on Mesoblast’s broader cell therapy pipeline and execution risks.
We’ll now examine how Ryoncil’s early US...